Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $128

Benzinga Newsdesk www.benzinga.com Positive 86.5%

Neg 0% Neu 0% Pos 86.5%

Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $110 to $128.